N-(1-methyl-piperidin-3-yl)-formamide | 61609-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-methyl-piperidin-3-yl)-formamide
• 英文别名: Formamide, N-(1-methyl-3-piperidinyl)-；N-(1-methylpiperidin-3-yl)formamide
• CAS: 61609-32-3
• 化学式: C₇H₁₄N₂O
• 分子量: 142.201
• InChiKey: UYLZBHARFJJPHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS
  申请人：Deutsches Krebsforschungszentrum

  公开号：EP3992191A1

  公开（公告）日：2022-05-04

  The present invention relates to imidazo[4,5-c]quinoline compounds and to their use in the inhibition, regulation and/or modulation of signal transduction by ATM kinase and, in particular, for the treatment of ATM mediated diseases, especially cancer.

  本发明涉及咪唑[4,5-c]喹啉化合物及其在ATM激酶信号转导的抑制、调节和/或调节中的使用，特别是用于治疗ATM介导的疾病，尤其是癌症。
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。
• SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER
  申请人：iPharma (H.K.) Limited

  公开号：EP2367800B9

  公开（公告）日：2021-10-20
• US7375222B2
  申请人：——

  公开号：US7375222B2

  公开（公告）日：2008-05-20
• [EN] PYRAZINE DERIVATIVES - 954<br/>[FR] DÉRIVÉS DE PYRAZINE - 954
  申请人：ASTRAZENECA AB

  公开号：WO2009007390A2

  公开（公告）日：2009-01-15

  The invention concerns pyrazine derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of G1, G2, R1, m, R2, R3, n and R4 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.